Jump to content

User:Mr. Ibrahem/Ixazomib

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Ixazomib
Clinical data
Trade namesNinlaro
Other namesIxazomib citrate, MLN2238
AHFS/Drugs.comMonograph
MedlinePlusa616008
License data
Pregnancy
category
  • Use is not recommended
Routes of
administration		By mouth (capsules)
Drug classProteasome inhibitor[1]
Legal status
Legal status
  • US: ℞-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability58%[2]
Protein binding99%
MetabolismHepatic (CYP: 3A4 (42%), 1A2 (26%), 2B6 (16%) and others)
Elimination half-life9.5 days
ExcretionUrine (62%), faeces (22%)
Identifiers
  • N2-(2,5-Dichlorobenzoyl)-N-[(1R)-1-(dihydroxyboryl)-3-methylbutyl]glycinamide
Chemical and physical data
FormulaC14H19BCl2N2O4
Molar mass361.03 g·mol−1
3D model (JSmol)
  • B([C@H](CC(C)C)NC(=O)CNC(=O)c1cc(ccc1Cl)Cl)(O)O
  • InChI=1S/C14H19BCl2N2O4/c1-8(2)5-12(15(22)23)19-13(20)7-18-14(21)10-6-9(16)3-4-11(10)17/h3-4,6,8,12,22-23H,5,7H2,1-2H3,(H,18,21)(H,19,20)/t12-/m0/s1
  • Key:MXAYKZJJDUDWDS-LBPRGKRZSA-N

Ixazomib, sold under the brand name Ninlaro, is a medication used to treat multiple myeloma.[1] It is used together with lenalidomide and dexamethasone in people who have failed other treatment.[1] It is taken by mouth.[3]

Common side effects include diarrhea, constipation, low platelets, low white blood cells, peripheral neuropathy, nausea, and swelling.[1] Other side effects may include liver problems.[3] Use in pregnancy may harm the baby.[3] It is a proteasome inhibitor and works by preventing protein breakdown in cells.[1]

Ixazomib was approved for medical use in the United States in 2015 and Europe in 2016.[3][1] In the United Kingdom 4 weeks of treatment costs the NHS about £6,300 as of 2021.[4] In the United States this amount costs about 11,400 USD.[5]

References[edit]

  1. ^ a b c d e f g h "Ninlaro". European Medicines Agency. Archived from the original on 14 November 2021. Retrieved 1 December 2021.
  2. ^ "Ninlaro- ixazomib capsule". DailyMed. 24 March 2020. Archived from the original on 27 October 2020. Retrieved 19 August 2020.
  3. ^ a b c d "Ixazomib Citrate Monograph for Professionals". Drugs.com. Archived from the original on 13 May 2021. Retrieved 26 November 2021.
  4. ^ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1009. ISBN 978-0857114105.
  5. ^ "Ninlaro Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 21 August 2021. Retrieved 1 December 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Ixazomib&oldid=1215380276"